PredicTx Health

About

PredicTx Health is an AI-powered precision oncology spin-out that personalises chemotherapy dosing by analysing patient body composition from CT scans.

Mission

PredicTx Health is a University of Melbourne spin-out that has built what it calls the world’s first AI-powered precision oncology platform. The software analyses standard CT scans with machine learning to quantify a patient’s muscle and bone composition, replacing the traditional body-surface-area approach to chemotherapy dosing. By combining radiomics, clinical data and predictive modelling, it enables oncologists to tailor chemo doses to individual physiology, aiming to reduce toxicity from overdosing and improve efficacy lost through underdosing. The company was co-founded by Professor Justin Yeung of Western Health and serial health-tech entrepreneur Abhijeet Waykar using research developed at the University. PredicTx will spend the next 12–18 months on clinical validation at Western Health, pilot deployments with cancer centres in Australia and India, and preparation of regulatory submissions to the TGA and CE. The new capital will also fund team expansion in AI engineering and clinical operations to accelerate product readiness and international scaling. To date, PredicTx has secured $1.6 million in pre-Seed financing to support these efforts.

Quick Facts